Look back at pharma news in the week to July 3, 2020

5 July 2020

By Barbara Obstoj-Cardwell. Editor

Last week saw Gilead Sciences’ chief executive outline pricing for developed countries for its remdesivir in the treatment of COVID-19, and the US Food and Drug Administration issue new clinical guidelines for drugmakers developing vaccines for the novel coronavirus. Heron Therapeutics had a major disappointment last Monday, when the FDA issued a complete response letter (CRL) regarding its post-operative pain candidate HTX-011. Intercept Pharmaceuticals also received a CRL the same day for its non-alcoholic steatohepatitis (NASH) candidate. There was better news for Akero Therapeutics, which presented encouraging new data on its NASH candidate AKR-001.

Gilead finally prices its COVID-19 drug

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK